Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares (ZJYL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
01/09/2026: ZJYL (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit 34.41% | Avg. Invested days 22 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 01/09/2026 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 101.74M USD | Price to earnings Ratio 32.49 | 1Y Target Price - |
Price to earnings Ratio 32.49 | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 10.76 | 52 Weeks Range 0.56 - 4.38 | Updated Date 06/29/2025 |
52 Weeks Range 0.56 - 4.38 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.02 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 15.64% | Operating Margin (TTM) 18.61% |
Management Effectiveness
Return on Assets (TTM) 5.78% | Return on Equity (TTM) 13.02% |
Valuation
Trailing PE 32.49 | Forward PE - | Enterprise Value 86163622 | Price to Sales(TTM) 4.33 |
Enterprise Value 86163622 | Price to Sales(TTM) 4.33 | ||
Enterprise Value to Revenue 3.67 | Enterprise Value to EBITDA 21.62 | Shares Outstanding 156547008 | Shares Floating 37824910 |
Shares Outstanding 156547008 | Shares Floating 37824910 | ||
Percent Insiders 75.84 | Percent Institutions 0.64 |
Upturn AI SWOT
JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares
Company Overview
History and Background
Jin Medical International Ltd. (NASDAQ: JMEI) was incorporated in 2014 and is based in Shenzhen, China. The company is primarily engaged in the research and development, manufacturing, and sale of innovative medical devices, with a particular focus on cardiovascular and cerebrovascular diseases. Significant milestones would include its establishment and subsequent development of its product pipeline and market entry.
Core Business Areas
- Medical Device Manufacturing: The company focuses on the development, production, and sale of advanced medical devices. This includes products designed for the diagnosis and treatment of cardiovascular and cerebrovascular diseases, aiming to provide minimally invasive solutions.
- Research and Development: Jin Medical invests in R&D to innovate and improve its medical device offerings, with a focus on addressing unmet needs in the cardiovascular and cerebrovascular fields.
Leadership and Structure
Information regarding the specific leadership team and detailed organizational structure for JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares is not readily available in public domain sources for a concise overview. Typically, such companies have a CEO, CFO, and a board of directors overseeing operations.
Top Products and Market Share
Key Offerings
- Cardiovascular and Cerebrovascular Medical Devices: Jin Medical designs, manufactures, and sells a range of medical devices. These are intended for the diagnosis and treatment of cardiovascular and cerebrovascular diseases. Specific product names and detailed market share data are not publicly available in a structured format, but their focus is on interventional devices. Competitors in this space are numerous and include large global medical device companies as well as specialized Chinese manufacturers.
Market Dynamics
Industry Overview
The medical device industry, particularly in China, is experiencing robust growth driven by an aging population, increasing prevalence of chronic diseases like cardiovascular and cerebrovascular conditions, and government support for domestic innovation. The market for interventional cardiology and neurology devices is highly competitive and capital-intensive.
Positioning
Jin Medical aims to position itself as an innovator in the Chinese medical device market, focusing on niche but high-demand areas like cardiovascular and cerebrovascular treatments. Their competitive advantage lies in their R&D capabilities and focus on developing minimally invasive devices. However, they face intense competition from established global players and rapidly growing domestic companies.
Total Addressable Market (TAM)
The total addressable market for cardiovascular and cerebrovascular medical devices in China is substantial and growing, driven by demographic trends and increasing healthcare expenditure. While specific TAM figures for Jin Medical's product categories are not readily available, the overall market is in the billions of USD. Jin Medical is positioned to capture a segment of this market through its specialized product offerings.
Upturn SWOT Analysis
Strengths
- Focus on high-growth areas (cardiovascular and cerebrovascular diseases)
- Investment in research and development for innovative devices
- Potential for domestic market penetration in China
Weaknesses
- Limited brand recognition compared to global competitors
- Reliance on specific product lines
- Potential challenges in scaling manufacturing and distribution
- Limited publicly available financial and operational data
Opportunities
- Increasing demand for interventional medical devices in China
- Government initiatives to promote domestic medical device manufacturing
- Expansion into new product categories or therapeutic areas
- Potential partnerships or collaborations
Threats
- Intense competition from established domestic and international players
- Regulatory hurdles and changes in healthcare policies
- Pricing pressures in the Chinese market
- Technological advancements by competitors
- Economic downturns impacting healthcare spending
Competitors and Market Share
Key Competitors
- MicroPort Scientific Corporation (US: MCRT)
- Shanghai Weigao Group Medical Polymer Company Limited (HK: 1066)
- Terumo Corporation (JP: 4544)
Competitive Landscape
JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares operates in a highly competitive landscape. Its advantages lie in its specialized product focus and potential for agility as a smaller player. However, it faces challenges in terms of scale, brand recognition, and established distribution networks that its larger competitors possess. The ability to innovate and secure regulatory approvals will be crucial.
Growth Trajectory and Initiatives
Historical Growth: The growth trajectory for JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares is tied to the success of its product development, regulatory approvals, and market adoption within China. Information on historical revenue and profit growth is not readily available for a clear trend analysis.
Future Projections: Future projections for JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares would depend on its ability to successfully launch and scale its innovative medical devices. Analyst estimates and specific growth targets are not widely published.
Recent Initiatives: Recent initiatives likely focus on R&D for new products, obtaining regulatory approvals, and expanding its sales and distribution network within China's competitive healthcare market.
Summary
JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares operates in the growing Chinese medical device market, focusing on cardiovascular and cerebrovascular solutions. While it has potential in a high-demand sector, the company faces significant challenges from established competitors and limited public financial transparency. Its success hinges on successful product innovation, market penetration, and navigating a complex regulatory environment. Investors should be aware of the inherent risks and competitive pressures in this industry.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings (SEC EDGAR)
- Financial news outlets
- Industry analysis reports
- Publicly available company websites
Disclaimers:
This analysis is based on publicly available information and is intended for informational purposes only. It does not constitute investment advice. Financial data may be incomplete or outdated. Investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2023-03-28 | Chairman of the Board, President & CEO Mr. Erqi Wang | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 269 | Website https://www.zhjmedical.com |
Full time employees 269 | Website https://www.zhjmedical.com | ||
Jin Medical International Ltd. engages in the design, development, manufacture, and sale of wheelchair and other living aids products for people with disabilities, the elderly, and people recovering from injury. The company offers wheelchairs and wheelchair components; oxygen concentrators, bath aids, and rehabilitative devices, as well as infrastructures for shared wheelchairs and other shared health products; oxygen chambers and beauty instruments; and shampoo instruments and nano thermal therapy chambers. It operates in China, Japan, the United States, Hong Kong, Singapore, Korea, Australia, and internationally. The company was founded in 2006 and is based in Changzhou, China. Jin Medical International Ltd. is a subsidiary of Jolly Harmony Enterprises Limited.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.